Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Parasitology ; 145(9): 1251-1259, 2018 08.
Article in English | MEDLINE | ID: mdl-29400267

ABSTRACT

Several ortho-naphthoquinones (o-NQs) have trypanocidal activity against Trypanosoma cruzi, the aetiological agent of Chagas disease. Previously, we demonstrated that the aldo-keto reductase from this parasite (TcAKR) reduces o-NQs, such as ß-lapachone (ß-Lap) and 9,10-phenanthrenequinone (9,10-PQ), with concomitant reactive oxygen species (ROS) production. Recent characterization of TcAKR activity and expression in two T. cruzi strains, CL Brener and Nicaragua, showed that TcAKR expression is 2.2-fold higher in CL Brener than in Nicaragua. Here, we studied the trypanocidal effect and induction of several death phenotypes by ß-Lap and 9,10-PQ in epimastigotes of these two strains. The CL Brener strain was more resistant to both o-NQs than Nicaragua, indicating that greater TcAKR activity is unlikely to be a major influence on o-NQ toxicity. Evaluation of changes in ROS production, mitochondrial membrane potential, phosphatidylserine exposure and monodansylcadaverine labelling evidenced that ß-Lap and 9,10-PQ induce different death phenotypes depending on the combination of drug and T. cruzi strain analysed. To study whether TcAKR participates in o-NQ activation in intact parasites, ß-Lap and 9,10-PQ trypanocidal effect was next evaluated in TcAKR-overexpressing parasites. Only ß-Lap was more effective and induced greater ROS production in TcAKR-overexpressing epimastigotes than in controls, suggesting that TcAKR may participate in ß-Lap activation.


Subject(s)
Aldo-Keto Reductases/metabolism , Naphthoquinones/pharmacology , Trypanocidal Agents/pharmacology , Trypanosoma cruzi/drug effects , Aldo-Keto Reductases/genetics , Animals , Chlorocebus aethiops , Membrane Potential, Mitochondrial/drug effects , Phenotype , Protozoan Proteins/genetics , Protozoan Proteins/metabolism , Reactive Oxygen Species/metabolism , Trypanosoma cruzi/enzymology , Trypanosoma cruzi/genetics , Vero Cells
2.
Antimicrob Agents Chemother ; 60(5): 2664-70, 2016 05.
Article in English | MEDLINE | ID: mdl-26856844

ABSTRACT

Benznidazole (Bz), the drug used for treatment of Chagas' disease (caused by the protozoan Trypanosoma cruzi), is activated by a parasitic NADH-dependent type I nitroreductase (NTR I). However, several studies have shown that other enzymes are involved. The aim of this study was to evaluate whether the aldo-keto reductase from T. cruzi (TcAKR), a NADPH-dependent oxido-reductase previously described by our group, uses Bz as the substrate. We demonstrated that both recombinant and native TcAKR enzymes reduce Bz by using NADPH, but not NADH, as a cofactor. TcAKR-overexpressing epimastigotes showed higher NADPH-dependent Bz reductase activity and a 50% inhibitory concentration (IC50) value for Bz 1.8-fold higher than that of the controls, suggesting that TcAKR is involved in Bz detoxification instead of activation. To understand the role of TcAKR in Bz metabolism, we studied TcAKR expression and NADPH/NADH-dependent Bz reductase activities in two T. cruzi strains with differential susceptibility to Bz: CL Brener and Nicaragua. Taking into account the results obtained with TcAKR-overexpressing epimastigotes, we expected the more resistant strain, Nicaragua, to have higher TcAKR levels than CL Brener. However, the results were the opposite. CL Brener showed 2-fold higher TcAKR expression and 5.7-fold higher NADPH-Bz reduction than the Nicaragua strain. In addition, NADH-dependent Bz reductase activity, characteristic of NTR I, was also higher in CL Brener than in Nicaragua. We conclude that although TcAKR uses Bz as the substrate, TcAKR activity is not a determinant of Bz resistance in wild-type strains and may be overcome by other enzymes involved in Bz activation, such as NADPH- and NADH-dependent reductases.


Subject(s)
Nitroimidazoles/metabolism , Trypanosoma cruzi/enzymology , Aldehyde Reductase/genetics , Aldehyde Reductase/metabolism , Aldo-Keto Reductases , Chagas Disease/drug therapy , Chagas Disease/metabolism , DNA, Protozoan/genetics , Nitroimidazoles/pharmacology , Nitroreductases/genetics , Nitroreductases/metabolism , Trypanocidal Agents/metabolism , Trypanocidal Agents/pharmacology
3.
Essays Biochem ; 51: 15-30, 2011.
Article in English | MEDLINE | ID: mdl-22023439

ABSTRACT

The causative agent of Chagas disease, Trypanosoma cruzi, metabolizes glucose through two major pathways: glycolysis and the pentose phosphate pathway. Glucose is taken up via one facilitated transporter and its catabolism by the glycolytic pathway leads to the excretion of reduced products, succinate and l-alanine, even in the presence of oxygen; the first six enzymes are located in a peroxisome-like organelle, the glycosome, and the lack of regulatory controls in hexokinase and phosphofructokinase results in the lack of the Pasteur effect. All of the enzymes of the pentose phosphate pathway are present in the four major stages of the parasite's life cycle, and some of them are possible targets for chemotherapy. The gluconeogenic enzymes phosphoenolpyruvate carboxykinase and fructose-1,6-bisphosphatase are present, but there is no reserve polysaccharide.


Subject(s)
Enzymes/metabolism , Glucose/metabolism , Trypanosoma cruzi/metabolism , Alanine/metabolism , Animals , Chagas Disease/parasitology , Fructose-Bisphosphatase/metabolism , Humans , Microbodies/metabolism , Pentose Phosphate Pathway , Trypanosoma cruzi/pathogenicity
4.
Mol Biochem Parasitol ; 173(2): 132-41, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20595031

ABSTRACT

Drugs currently used for treatment of Trypanosoma cruzi infection, the ethiological agent of Chagas' disease, have shown side effects and variable efficiency. With the aim to describe parasite enzymes involved in the mechanisms of action of trypanocidal drugs and since it has been reported that reductases are crucial in their metabolism, we attempted to identify novel NADPH-dependent oxido-reductases from T. cruzi. The percolation of a soluble fraction of epimastigote lysates through a Cibacron Blue-Sepharose column followed by elution by NADPH yielded a predominant protein with an apparent molecular weight of 32 kDa. This protein was identified by MALDI-TOF as an aldo-keto reductase (AKR) and hence denominated TcAKR. TcAKR was mainly localized in the cytosol and was also present in trypomastigote and amastigote lysates. The recombinant TcAKR (recTcAKR) showed NADPH-dependent reductase activity with the AKR substrates 4-nitrobenzaldehyde and 2-dihydroxyacetone. The saturation curves for both substrates were consistent with the Michaelis-Menten model. We also tested whether recTcAKR may reduce naphthoquinones (NQ), since many of these compounds have displayed important trypanocidal activity. recTcAKR reduced o-NQ (1,2-naphthoquinone, 9,10-phenanthrenquinone and beta-lapachone) with concomitant generation of free radicals but did not exhibit affinity for p-NQ (5-hydroxy-1,4-naphthoquinone, 2-hydroxy-1,4-naphthoquinone, alpha-lapachone and menadione). The substrate saturation curve with o-NQ fitted to a sigmoidal curve, suggesting that recTcAKR presents a cooperative behavior. In addition, three peaks assigned to monomers, dimers and tetramers were obtained when recTcAKR was submitted to a Superose 12 gel chromatography column. TcAKR is the first member of the AKR family described in T. cruzi. Our results indicate that this enzyme may participate in the mechanisms of action of trypanocidal drugs.


Subject(s)
Alcohol Oxidoreductases/genetics , Alcohol Oxidoreductases/metabolism , Benzoquinones/metabolism , Protozoan Proteins/genetics , Protozoan Proteins/metabolism , Trypanosoma cruzi/enzymology , Alcohol Oxidoreductases/chemistry , Alcohol Oxidoreductases/isolation & purification , Aldehyde Reductase , Aldo-Keto Reductases , Animals , Benzaldehydes/metabolism , Chromatography, Gel , Chromatography, Liquid/methods , Cloning, Molecular , Coenzymes/metabolism , DNA, Protozoan/chemistry , DNA, Protozoan/genetics , Dihydroxyacetone/metabolism , Humans , Male , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Molecular Weight , NADP/metabolism , Oxidation-Reduction , Protein Multimerization , Protozoan Proteins/chemistry , Protozoan Proteins/isolation & purification , Sequence Analysis, DNA , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
5.
Mol Biochem Parasitol ; 135(2): 211-9, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15110462

ABSTRACT

Poly(ADP-ribose)polymerase has been purified more than 160000-fold from Crithidia fasciculata. This is the first PARP isolated to apparent homogeneity from trypanosomatids. The purified enzyme absolutely required DNA for catalytic activity and histones enhanced it 2.5-fold, when the DNA:histone ratio was 1:1.3. The enzyme required no magnesium or any other metal ion cofactor. The apparent molecular mass of 111 kDa, determined by gel filtration would correspond to a dimer of two identical 55-kDa subunits. Activity was inhibited by nicotinamide, 3-aminobenzamide, theophylline, thymidine, xanthine and hypoxanthine but not by adenosine. The enzyme was localized to the cell nucleus. Our findings suggest that covalent poly(ADP-ribosyl)ation of PARP itself or DNA topoisomerase I resulted in the inhibition of their activities and provide an initial biochemical characterization of this covalent post-translational modification in trypanosomatids.


Subject(s)
Crithidia fasciculata/enzymology , DNA Topoisomerases, Type I/metabolism , Poly(ADP-ribose) Polymerases/metabolism , Protozoan Proteins/metabolism , Animals , Chromatography, Ion Exchange , Electrophoresis, Polyacrylamide Gel , Kinetics , Poly(ADP-ribose) Polymerases/isolation & purification , Protozoan Proteins/isolation & purification
SELECTION OF CITATIONS
SEARCH DETAIL
...